Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R D, CDMO Commercial Manufacturing Accelerates Revenue Growth
- Written by PR Newswire
![]() |
Results Highlights for Interim Results ended 30 June 2026Revenue reached RMB1,006.5 million, increasing by 21.0% YoYGross profit amounted to RMB341.7 million, increasing by 0.7% YoYGross profit margin was 34.0%
HONG KONG, Aug. 26, 2026 /PRNewswire/ -- On August 26, 2026, Viva Biotech Holdings Group ("the Group" or "the Company", stock code:...















